TCRT alaunos.com: יחס שווי פעילות לרווח לפני ריבית, מסים ופחת
The daily price chart for Alaunos Therapeutics (TCRT) shows an EV/EBITDA ratio of 0.00, driven by US trade restrictions on high-tech exports to Asia and stringent biosafety regulations. Current volatility stems from a revision of scientific strategies independent of market cycles. Meanwhile, the business relies on streamlined cryogenic logistics for biomaterials, ensuring process stability and future profitability.
alaunos.com (TCRT) - פילוחי מדדים ודוחות פיננסיים
Alaunos Therapeutics (TCRT) leverages the robust R&D potential of leading biochemists, which minimizes personnel risks during immunotherapy development. Analyzing this EV/EBITDA multiple chart, an investor can see the ratio of the company's total value (market capitalization and debt) to its operating profit before interest and taxes. This indicator allows for a real-time assessment of the asset's actual value accounting for debt load, determining the efficiency of investments in the high-tech sector.
